Advantageous for consumers of CGA is its proposed capability to modulate glucose in the bloodstream following the consumption of carbohydrate-based meals. Minimization of glucose output as a major facilitator in healthy weight management has, all things considered, long been recognized, hence the low simple-carbohydrate mandate most diets espouse. In a single study, researchers (1) investigated whether Svetol could decrease post-prandial (following meals) blood glucose concentration in humans. In their study, 15 men and women aged between 18 and 70 were submitted to a glucose tolerance test pre and post the use of Svetol (200mg of Svetol in three daily doses – 600mg per day – over a 40 day period). Physical exercise levels and diet for all participants remained unchanged during this period. After the 40-day supplementation period it was discovered that post-load glycaemia (or blood sugar levels following a meal) had decreased significantly compared to the post-load glycaemia obtained before the supplementation; 66% of participants also experienced a median improvement of 48% in blood sugar concentration following meals. For ten participants, glucose tolerance was highly and significantly decreased after supplementing with the Svetol, compared to the glucose tolerance readings obtained before they had supplemented with Svetol. Finally, an average loss of approximately 3lbs bodyweight was noted among all group members, regardless of their unchanged dieting and exercise pattern.
Svetol and Body Mass
In a double-blind placebo-controlled clinical trial, which assessed the effectiveness of Svetol supplementation on weight management (2), researchers discovered a substantial Body Mass Index (BMI) reduction among participants in comparison to the study’s control group.
In this study, 50 volunteers of both sexes, aged from 19 to 75 and with BMI’s surpassing 25 (placing them in the overweight category) were split into two randomized groups: a control group of 20 participants who received a placebo and a treated group of 30, who were given 200mg of Svetol brand Green Coffee Bean Extract (GCBE) two times a day for 60 days with main meals (thus each Svetol subject received the desired daily amount of CGA’s: 400mg). For each subject – both control and treated – changes in body weight, BMI and Muscle Mass/Fat Mass (MM/FM) ratio were recorded at the study’s commencement and completion.
After the 60-day treatment period the Svetol subjects were found to have favorably reduced their bodyweight by an average of 5.7% (4.97kg/10.96lb) whereas the control group, who had received 200mg of maltodextrin in place of the Svetol twice daily, showed a mean lowering of 2.45kg/5.40lb. MM/FM ratio had also significantly improved for all treated participants.
It was determined that Svetol has the capacity to exacerbate the impact of a bland low calorie diet in overweight subjects, a finding which, say the researchers, could be explained by a rise in the intake of fatty deposits and an offsetting of their accumulation through Svetol brand Green Coffee Bean Extract (GCBE) supplementation.
Bioavailability of CGA
As revealed in the above two studies, Chlorogenic Acids (CGAs) seem to successfully modulate blood glucose levels to encourage body fat utilization to effectively manage body weight. In a more recent study researchers (3) sought to assess the specific bioavailability of CGAs in human subjects by evaluating the pharmacokinetic profile of CGAs in blood plasma and urine of 10 healthy adults (five male and five female) for 8 hours following the consumption of a decaffeinated coffee extract containing 170mg of CGA. After acute ingestion of the coffee extract, each subject was to be tested for bio-available degrees of CGA compounds and metabolites. It was discovered that over 30% of the active CGA compounds, including metabolites such as 5-CQA and caffeic acid, ingested were recovered in plasma (with peak levels from 0.5 to 8 hours after treatment) and indentified in urine following treatment. This study, which revealed that the major CGA compounds present in green coffee are highly absorbed and metabolized in humans, demonstrated for the first time the high bioavailability of green coffee, even considering the relatively low experimental doses of 170mg that were given.
This study shows that the Chlorogenic Acids found in Green Coffee Bean Extract are taken up by, and effectively absorbed into, the body.
A Dosage Study
An additional study examined the efficacy and safety of high and low dose CGA supplementation on weight and body mass reduction among 16 overweight adult subjects, aged 22-46 (average BMI at the study’s commencement was 28.22). In a double-blind, placebo-controlled, linear dose, 22 week crossover study each subject received either 1050mg or 700mg of the green coffee bean extract (GCBE), or a placebo, in separate six-week treatment periods (followed by a two-week ‘washout’ period to prevent preceding treatments influencing the results). Body weight, body fat percentage and BMI were measured to ascertain any positive effects. No dietary changes were made by any subject during this study. In line with findings from other studies into CGA supplementation, all subjects were found to have lowered their BMI (-2.92kg/M2), body weight (a mean lowering of 8kg or 17.64lb) and body fat percentage (4.4% on average). All participants reported no unwanted effects linked to the green coffee extract consumption.
The researchers determined that the product tested may be an “effective nutraceutical in cutting weight in pre-obese adults, and may be a cost-effective means of preventing obesity in overweight adults.”
As said before, CGA supplementation has been shown to have a marked impact on weight loss through its inhibiting effect on glucose-6-phosphatase which, in turn, encourages the liberating of stored fat for energy. Though several studies’ findings supported this kind of action through human trials, further researchers (5) sought to ascertain whether a decaffeinated green coffee extract (Svetol) would inhibit hepatic glucose-6-phosphatase in vitro (studies conducted in laboratory conditions to isolate an element of an organism from its usual biological context). In this study, three concentrations were tested: the equivalent of 157mg, 315mg and 472mg (equivalent to the daily recommended Svetol intake) of Svetol per liter of solution. Following the incubation of human liver microsomes (with or without Svetol) it was determined that Svetol competitively inhibited glucose-6-phosphatase. The researchers concluded that their observed results are primarily associated with post meal blood glucose regulation and the fat burning action Svetol has shown in other studies.